

Madiha Iqbal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/838592/publications.pdf>

Version: 2024-02-01

39
papers

368
citations

933264

10
h-index

839398

18
g-index

40
all docs

40
docs citations

40
times ranked

633
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e89-e95.	0.2	2
2	Omission of day +11 methotrexate dose and allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/meta-analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 65-71.	1.3	2
3	Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. <i>Leukemia</i> , 2022, 36, 856-864.	3.3	26
4	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	0.8	2
5	New indications and platforms for CAR-T therapy in lymphomas beyond DLBCL. <i>EJHaem</i> , 2022, 3, 11-23.	0.4	2
6	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.2	2
7	In-field recurrences in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7556-7556.	0.8	2
8	Treatment with anti-spike monoclonal antibodies in allogeneic HCT and CAR T-cell recipients with mild to moderate COVID-19: The Mayo Clinic experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19049-e19049.	0.8	0
9	Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 668.e1-668.e6.	0.6	4
10	Intraocular involvement of Mantle cell lymphoma: A case report and literature review. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 147-152.	0.6	3
11	Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 95-103.	0.6	0
12	Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 167.e1-167.e12.	0.6	8
13	Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: A systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2021, 106, 40-48.	1.1	2
14	Diffuse large B-cell lymphoma with leukemic involvement.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19552-e19552.	0.8	0
15	Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	5
16	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021, 138, 1415-1415.	0.6	1
17	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	0.6	2
18	A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 2495-2495.	0.6	1

#	ARTICLE	IF	CITATIONS
19	A Calcineurin Inhibitor Free Graft Versus Host Disease (GVHD) Prophylaxis for Patients Undergoing Matched Related (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplant (Allo-HCT). <i>Blood</i> , 2021, 138, 3893-3893.	0.6	0
20	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 76-82.	2.0	26
21	Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. <i>Current Research in Translational Medicine</i> , 2020, 68, 159-170.	1.2	24
22	Impact of Depression and Anxiety on Opioid Use in Hospitalized Hematopoietic Cell Transplantation Recipients. <i>Psychosomatics</i> , 2020, 61, 363-370.	2.5	1
23	Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e694-e711.	0.2	13
24	Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2020, 136, 42-43.	0.6	0
25	Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience. <i>Blood</i> , 2020, 136, 33-34.	0.6	4
26	First Report of Hereditary Lysozyme Amyloidosis in a South Asian Family. <i>Case Reports in Hematology</i> , 2019, 2019, 1-5.	0.3	4
27	Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2019, 9, 75.	2.8	43
28	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1-Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1695-1700.	2.0	14
29	Additional autoimmune disorders in patients with acquired autoimmune thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2019, 94, E172-E174.	2.0	17
30	Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 400-406.	0.6	15
31	Cytokine Release Syndrome: Current Perspectives. <i>ImmunoTargets and Therapy</i> , 2019, Volume 8, 43-52.	2.7	116
32	Successful Antimicrobial Treatment of Phlegmonous Gastritis: A Case Report and Literature Review. <i>Case Reports in Hematology</i> , 2018, 2018, 1-5.	0.3	19
33	Exploring Disease Biology in Hispanic Versus Non-Hispanic Patients with Diffuse Large B-Cell Lymphoma (DLBCL) to Explain Survival Disparities. <i>Blood</i> , 2018, 132, 4867-4867.	0.6	0
34	Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4869-4869.	0.6	0
35	Comparative Analysis on the Anti-Tumor Activity of Venetoclax and Obinutuzumab (VO) Versus Venetoclax and Rituximab (VR) in Primary CLL Cells, Ex Vivo. <i>Blood</i> , 2018, 132, 5558-5558.	0.6	0
36	Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care. <i>Blood</i> , 2018, 132, 4764-4764.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Impact of Depression or Anxiety on Opioid and Benzodiazepine Use in Hospitalized Hematopoietic Stem Cell Transplantation (HSCT) Recipients. <i>Blood</i> , 2018, 132, 4852-4852.	0.6	0
38	Opiate and Benzodiazepine Use during Hospitalization for Hematopoietic Stem Cell Transplantation (HSCT) Is Associated with Adverse Health Related Outcomes. <i>Blood</i> , 2018, 132, 5873-5873.	0.6	1
39	Clinical Characteristics, Prognostic Indicators, and Survival Outcomes in Intravascular Lymphoma: Mayo Clinic Experience (2003â€“2018). <i>American Journal of Hematology</i> , 0, , .	2.0	4